Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Revolution Medicines, Inc.
RVMD
$79.65
Name : Revolution Medicines, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $15,397,922,816.00
EPSttm : -5.19
finviz dynamic chart for RVMD
Revolution Medicines, Inc.
$79.65
0.03%
$0.02

Float Short %

9.12

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

-0.04

EPS Last/This Y

-1.96

EPS This/Next Y

-0.73

Price

79.67

Target Price

83.26

Analyst Recom

1

Performance Q

73.68

Relative Volume

0.36

Beta

0.99

Ticker: RVMD




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-02RVMD75.340.362.4343997
2025-12-03RVMD77.70.360.1443941
2025-12-04RVMD78.470.340.0646243
2025-12-05RVMD79.660.330.0948235
2025-12-08RVMD80.060.330.2448276
2025-12-09RVMD77.740.320.5848456
2025-12-10RVMD77.850.320.2048426
2025-12-11RVMD78.490.320.8848613
2025-12-12RVMD78.910.334.5548739
2025-12-15RVMD78.990.390.1650997
2025-12-16RVMD77.570.380.2852175
2025-12-17RVMD76.740.380.1652280
2025-12-18RVMD75.950.380.5752166
2025-12-19RVMD78.750.380.2452150
2025-12-22RVMD80.530.160.1338132
2025-12-23RVMD80.210.160.0638593
2025-12-26RVMD80.720.162.4939803
2025-12-29RVMD80.550.161.5940011
2025-12-30RVMD79.670.160.5740162
2025-12-31RVMD79.670.170.3240451
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-02RVMD75.31-42.6-255.6-5.54
2025-12-03RVMD77.69-42.6-311.4-5.54
2025-12-04RVMD78.50-42.6-280.2-5.54
2025-12-05RVMD79.64-42.6-286.4-5.54
2025-12-08RVMD80.06-42.6- -5.54
2025-12-09RVMD77.81-42.6-223.3-5.54
2025-12-10RVMD77.85-42.6-265.4-5.54
2025-12-11RVMD78.51-42.6-277.1-5.54
2025-12-12RVMD78.91-42.6-272.1-5.54
2025-12-15RVMD79.00-42.6-266.1-5.54
2025-12-16RVMD79.00-42.4-265.4-5.54
2025-12-17RVMD76.72-42.4-248.6-5.54
2025-12-18RVMD75.94-42.4-249.5-5.54
2025-12-19RVMD78.76-42.4-320.2-5.54
2025-12-22RVMD80.58-42.4-296.2-5.54
2025-12-23RVMD80.25-42.4-257.3-5.54
2025-12-26RVMD80.74-42.4-256.5-5.54
2025-12-29RVMD80.53-42.4-260.5-5.54
2025-12-30RVMD79.68-42.4-249.2-5.54
2025-12-31RVMD79.67-42.4-264.1-5.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-02RVMD-1.361.2210.58
2025-12-03RVMD-1.361.2210.58
2025-12-04RVMD-1.361.2210.58
2025-12-05RVMD-1.361.2210.58
2025-12-08RVMD-1.361.2410.58
2025-12-09RVMD-1.361.2410.58
2025-12-10RVMD-1.361.2410.16
2025-12-11RVMD-1.361.2410.16
2025-12-12RVMD-1.361.2410.16
2025-12-15RVMD-1.361.2410.16
2025-12-16RVMD-1.361.2410.16
2025-12-17RVMD-1.361.2410.16
2025-12-18RVMD-1.371.2410.16
2025-12-19RVMD-1.371.2410.16
2025-12-22RVMD-1.371.2410.16
2025-12-23RVMD-1.371.2410.16
2025-12-26RVMD-1.371.249.12
2025-12-29RVMD-1.371.249.12
2025-12-30RVMD-1.371.249.12
2025-12-31RVMD-1.371.249.12
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.61

Avg. EPS Est. Current Quarter

-1.6

Avg. EPS Est. Next Quarter

-1.65

Insider Transactions

-1.37

Institutional Transactions

1.24

Beta

0.99

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

Fair Value

Quality Score

5

Growth Score

22

Sentiment Score

79

Actual DrawDown %

2.8

Max Drawdown 5-Year %

-73.3

Target Price

83.26

P/E

Forward P/E

PEG

P/S

P/B

9.46

P/Free Cash Flow

EPS

-5.18

Average EPS Est. Cur. Y​

-5.54

EPS Next Y. (Est.)

-6.27

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.36

Return on Equity vs Sector %

-87.5

Return on Equity vs Industry %

-72.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

-264.1
Revolution Medicines, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 809
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today
news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance
stock history RVMD – Revolution Medicines, Inc. invest stock market
stock prices RVMD premarket after hours
ticker RVMD fair value insiders trading